Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Liquidity Ratios (Summary)

Abbott Laboratories, liquidity ratios (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Current ratio
Quick ratio
Cash ratio

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The liquidity position exhibits a general trend of contraction over the period from March 2022 through June 2026. While the initial quarters show a robust capacity to cover short-term obligations, a progressive decline in liquid asset coverage is observed, with the most significant deterioration occurring in the final year of the sequence.

Current Ratio
A peak of 2.01 was recorded in June 2022, followed by a period of relative stability between 1.60 and 1.82 through the end of 2024. A downward trend accelerates in 2025 and 2026, reaching a minimum of 1.38 by June 2026, which indicates a tightening of the overall working capital cushion.
Quick Ratio
This ratio mirrored the current ratio's trajectory, peaking at 1.33 in June 2022. Throughout 2023 and 2024, the ratio fluctuated near the 1.00 threshold. A notable deterioration is observed in the first half of 2026, where the ratio falls to 0.80, signifying that liquid assets excluding inventory are no longer sufficient to cover current liabilities.
Cash Ratio
The most significant erosion of liquidity is evident in the cash ratio. After reaching 0.75 in June 2022, the ratio trended downward to 0.47 by March 2024. Despite a period of stabilization around 0.53 throughout 2025, the ratio experiences a sharp decline to 0.31 by June 2026, reflecting a substantial reduction in the immediate cash available to meet short-term obligations.


Current Ratio

Abbott Laboratories, current ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The liquidity position of the organization exhibits a gradual decline in the current ratio over the analyzed period, moving from a peak of 2.01 in June 2022 to a low of 1.38 by June 2026. While the company maintained a healthy margin of safety throughout the period, the trajectory indicates a tightening of short-term liquidity.

Current Ratio Trends
The current ratio experienced initial volatility in 2022, peaking at 2.01 before stabilizing between 1.60 and 1.82 through most of 2023 and 2024. However, a more pronounced downward trend emerged in the latter part of the series, with the ratio falling consistently from 1.82 in June 2025 to 1.38 by June 2026. This indicates a reduction in the capacity to cover short-term obligations using short-term assets.
Current Asset Analysis
Current assets remained relatively stable, fluctuating within a range of approximately 22.3 billion USD to 26.0 billion USD. A slight upward trend was observed between March 2024 and December 2025, reaching a peak of 25.9 billion USD, before declining to 24.5 billion USD by June 2026. The lack of substantial growth in assets relative to liabilities contributed to the overall compression of the liquidity ratio.
Current Liability Analysis
A steady upward trend in current liabilities is the primary driver of the declining liquidity ratio. Liabilities increased from 12.6 billion USD in March 2022 to 17.8 billion USD by June 2026. This growth became particularly accelerated between September 2025 and March 2026, where liabilities rose from 14.5 billion USD to 18.3 billion USD, significantly impacting the current ratio during the final stages of the analyzed period.

In summary, the reduction in the current ratio is not a result of dwindling assets, but rather a consequence of a significant increase in short-term liabilities. Although the ratio remains above 1.0, suggesting the organization can still meet its current obligations, the trend suggests a shift toward a more leveraged short-term financial position.



Quick Ratio

Abbott Laboratories, quick ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Short-term investments
Trade receivables, less allowances
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The liquidity position of the organization exhibited significant volatility between March 2022 and June 2026, characterized by an initial period of stability followed by a notable decline in the final quarters. While the quick ratio remained predominantly at or above the 1.0 threshold for the majority of the analyzed period, a downward trajectory became evident starting in late 2025.

Quick Ratio Trend Analysis
The quick ratio reached a peak of 1.33 in June 2022, indicating a strong capacity to meet short-term obligations without relying on inventory sales. For the duration of 2023 and 2024, the ratio fluctuated narrowly around the 1.00 mark, representing a neutral liquidity position where liquid assets roughly equaled current liabilities. A secondary recovery was observed in early 2025, with the ratio climbing to 1.14 by June 2025, before entering a sharp decline to 0.80 by June 2026.
Quick Asset Dynamics
Total quick assets demonstrated cyclical movements, starting at 15,337 million USD in March 2022 and reaching a high of 16,868 million USD by December 2025. A period of contraction occurred throughout 2023 and early 2024, with assets bottoming out at 13,256 million USD in March 2024. Despite a recovery through 2025, a significant reduction in liquid assets to 14,202 million USD occurred by June 2026.
Current Liabilities Growth
Current liabilities remained relatively stable between 12,000 million USD and 15,000 million USD from March 2022 through December 2024. However, a substantial increase in short-term obligations is observed starting in early 2026, with liabilities peaking at 18,377 million USD in March 2026. This escalation in liabilities is the primary driver behind the deterioration of the liquidity ratio in the final stages of the period.
Liquidity Divergence
The most critical shift occurred between December 2025 and June 2026. During this window, the convergence of declining quick assets and rapidly increasing current liabilities led the quick ratio to fall below the 1.0 benchmark, reaching 0.80. This suggests a diminished ability to cover immediate liabilities using only the most liquid assets compared to the stronger positions held between 2022 and 2025.


Cash Ratio

Abbott Laboratories, cash ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Short-term investments
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The analysis of the cash ratio reveals a significant long-term decline in immediate liquidity. While the period began with a relatively strong position, there is a clear trend toward a diminished capacity to meet short-term obligations using only cash and cash equivalents.

Cash Asset Volatility
Total cash assets reached a peak of 10,170 million USD in December 2022 before entering a period of fluctuation. After a decline to 7,047 million USD in September 2023, assets recovered to 8,939 million USD by December 2025, followed by a sharp decrease to 5,603 million USD by June 2026.
Liability Expansion
Current liabilities exhibited a general upward trajectory, increasing from 12,647 million USD in March 2022 to a peak of 18,377 million USD in March 2026. This growth in short-term obligations has placed sustained pressure on liquidity metrics throughout the observed period.
Cash Ratio Erosion
The cash ratio peaked at 0.75 in June 2022. A gradual erosion occurred through 2023 and 2024, during which the ratio primarily fluctuated between 0.47 and 0.56. A precipitous drop is observed in the first half of 2026, with the ratio falling to 0.40 in March and reaching a period low of 0.31 by June 2026.

The convergence of diminishing cash reserves and rising current liabilities results in a weakened liquidity profile. The sharp contraction of the cash ratio in the final quarters indicates a heightened reliance on other current assets or external financing to satisfy short-term debts.